Licensing
Enkam Pharmaceuticals, a privately held Danish company specialising in cancer and central nervous system disorders, has signed a licensing and development agreement with Stemcell Technologies Inc, a Canadian company that specialises in cell culture media, cell separation products and reagents for life science research.
Enkam’s Protein Mimetic Technology Platform will be used for the rapid creation of active peptides that are able to mimic specific functions of larger proteins, which Stemcell will commercialise. Financial terms were not disclosed.
Receive our Policy Bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
